Aveanna Healthcare (NASDAQ:AVAH) Insider Edwin Reisz Sells 16,755 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 16,755 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $8.36, for a total value of $140,071.80. Following the transaction, the insider owned 1,355,329 shares in the company, valued at $11,330,550.44. This trade represents a 1.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Aveanna Healthcare Price Performance

Shares of NASDAQ AVAH opened at $8.08 on Friday. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. The firm has a fifty day moving average of $8.92 and a 200 day moving average of $7.49. The firm has a market cap of $1.69 billion, a PE ratio of 22.44 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a one year low of $3.67 and a one year high of $10.32.

Aveanna Healthcare (NASDAQ:AVAH) last announced its earnings results on Monday, May 22nd. The company reported $0.04 earnings per share (EPS) for the quarter. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. The business had revenue of $450.53 million for the quarter. As a group, research analysts predict that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current fiscal year.

Institutional Trading of Aveanna Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Transatlantique SA acquired a new position in shares of Aveanna Healthcare during the 1st quarter valued at about $25,000. Quantbot Technologies LP acquired a new stake in Aveanna Healthcare during the second quarter worth about $43,000. Diversified Trust Co acquired a new stake in Aveanna Healthcare during the second quarter worth about $57,000. Jump Financial LLC purchased a new position in Aveanna Healthcare during the first quarter worth about $59,000. Finally, MQS Management LLC acquired a new position in Aveanna Healthcare in the 2nd quarter valued at about $59,000. 87.96% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Wall Street Analyst Weigh In

Several research firms have commented on AVAH. Royal Bank Of Canada boosted their price objective on Aveanna Healthcare from $8.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Friday, October 24th. Raymond James Financial reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Aveanna Healthcare in a research note on Friday, December 5th. Jefferies Financial Group increased their price objective on Aveanna Healthcare from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday. Finally, Truist Financial upped their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a report on Friday, November 7th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.69.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.